AU2004216340B9 - PTEN inhibitor or Maxi-K channels opener - Google Patents

PTEN inhibitor or Maxi-K channels opener Download PDF

Info

Publication number
AU2004216340B9
AU2004216340B9 AU2004216340A AU2004216340A AU2004216340B9 AU 2004216340 B9 AU2004216340 B9 AU 2004216340B9 AU 2004216340 A AU2004216340 A AU 2004216340A AU 2004216340 A AU2004216340 A AU 2004216340A AU 2004216340 B9 AU2004216340 B9 AU 2004216340B9
Authority
AU
Australia
Prior art keywords
compound
salt
maxi
bond
dihydrocarbostyril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004216340A
Other languages
English (en)
Other versions
AU2004216340A1 (en
AU2004216340B2 (en
Inventor
Ki Whan Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2004216340A1 publication Critical patent/AU2004216340A1/en
Application granted granted Critical
Publication of AU2004216340B2 publication Critical patent/AU2004216340B2/en
Publication of AU2004216340B9 publication Critical patent/AU2004216340B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004216340A 2003-02-25 2004-02-24 PTEN inhibitor or Maxi-K channels opener Ceased AU2004216340B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44943503P 2003-02-25 2003-02-25
US60/449,435 2003-02-25
US44958903P 2003-02-26 2003-02-26
US60/449,589 2003-02-26
PCT/JP2004/002146 WO2004075897A1 (en) 2003-02-25 2004-02-24 Pten inhibitor or maxi-k channels opener

Publications (3)

Publication Number Publication Date
AU2004216340A1 AU2004216340A1 (en) 2004-09-10
AU2004216340B2 AU2004216340B2 (en) 2008-07-31
AU2004216340B9 true AU2004216340B9 (en) 2008-09-18

Family

ID=32930512

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004216340A Ceased AU2004216340B9 (en) 2003-02-25 2004-02-24 PTEN inhibitor or Maxi-K channels opener

Country Status (19)

Country Link
US (3) US7825130B2 (https=)
EP (1) EP1599205B1 (https=)
JP (3) JP4590397B2 (https=)
KR (1) KR101031163B1 (https=)
CN (2) CN1780623B (https=)
AR (1) AR043379A1 (https=)
AT (1) ATE345800T1 (https=)
AU (1) AU2004216340B9 (https=)
BR (1) BRPI0407832A (https=)
CA (1) CA2515590C (https=)
CY (1) CY1106294T1 (https=)
DE (1) DE602004003348T2 (https=)
DK (1) DK1599205T3 (https=)
ES (1) ES2276282T3 (https=)
MX (1) MXPA05008996A (https=)
MY (1) MY136863A (https=)
PT (1) PT1599205E (https=)
TW (1) TWI323660B (https=)
WO (1) WO2004075897A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
KR101441725B1 (ko) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
CN101932331B (zh) * 2008-01-17 2012-10-24 刘奎 卵泡体外成熟方法
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
WO2009117387A2 (en) * 2008-03-17 2009-09-24 The Trustees Of Columbia University In The City Of New York Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
US8367352B2 (en) 2008-06-06 2013-02-05 Children's Medical Center Corporation Promoting axon regeneration in the adult CNS through control of protein translation
WO2011044701A1 (en) 2009-10-16 2011-04-21 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
RU2015101100A (ru) 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
JP2017070404A (ja) * 2015-10-06 2017-04-13 アンディ チャオ トイレ床面の清潔な芳香パッド
WO2017199755A1 (ja) * 2016-05-19 2017-11-23 国立研究開発法人国立循環器病研究センター 認知症の予防及び／又は治療のための薬剤
WO2021230131A1 (ja) * 2020-05-11 2021-11-18 株式会社島津製作所 軽度認知障害治療剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277479A (en) * 1978-09-01 1981-07-07 Otsuka Pharmaceutical Co., Ltd. Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
WO1994014444A1 (fr) * 1992-12-24 1994-07-07 Otsuka Pharmaceutical Co., Ltd. Remede contre le psoriasis
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
JPH0653666B2 (ja) 1990-10-22 1994-07-20 大塚製薬株式会社 ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
JPH0614444A (ja) * 1992-06-25 1994-01-21 Central Japan Railway Co 電力ケーブル接続部の固定装置
JPH06239745A (ja) * 1992-12-24 1994-08-30 Otsuka Pharmaceut Co Ltd 乾癬治療剤
JPH0776584A (ja) 1993-09-07 1995-03-20 Otsuka Pharmaceut Co Ltd 内皮細胞障害抑制剤
JP3944257B2 (ja) 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
MXPA00010254A (es) * 1998-05-01 2002-08-06 R Cutler Neal Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6257985B1 (en) * 1999-10-01 2001-07-10 Rexnord Corporation Global shaft coupling
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
JP4159224B2 (ja) 2000-02-29 2008-10-01 三洋電機株式会社 食器洗浄機
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277479A (en) * 1978-09-01 1981-07-07 Otsuka Pharmaceutical Co., Ltd. Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
WO1994014444A1 (fr) * 1992-12-24 1994-07-07 Otsuka Pharmaceutical Co., Ltd. Remede contre le psoriasis
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction

Also Published As

Publication number Publication date
US8329731B2 (en) 2012-12-11
DE602004003348T2 (de) 2007-05-31
CN101829116B (zh) 2015-11-25
CN101829116A (zh) 2010-09-15
US20060154963A1 (en) 2006-07-13
BRPI0407832A (pt) 2006-02-14
DE602004003348D1 (de) 2007-01-04
JP4590397B2 (ja) 2010-12-01
TW200501954A (en) 2005-01-16
AR043379A1 (es) 2005-07-27
AU2004216340A1 (en) 2004-09-10
CN1780623B (zh) 2011-09-14
WO2004075897A1 (en) 2004-09-10
JP2010285456A (ja) 2010-12-24
CY1106294T1 (el) 2011-10-12
KR20050098960A (ko) 2005-10-12
ES2276282T3 (es) 2007-06-16
PT1599205E (pt) 2007-01-31
CN1780623A (zh) 2006-05-31
MY136863A (en) 2008-11-28
JP2006518732A (ja) 2006-08-17
JP2013082735A (ja) 2013-05-09
CA2515590C (en) 2011-09-13
MXPA05008996A (es) 2005-10-18
JP5566482B2 (ja) 2014-08-06
JP5208172B2 (ja) 2013-06-12
KR101031163B1 (ko) 2011-04-27
US7825130B2 (en) 2010-11-02
CA2515590A1 (en) 2004-09-10
TWI323660B (en) 2010-04-21
DK1599205T3 (da) 2007-03-26
HK1091409A1 (en) 2007-01-19
EP1599205A1 (en) 2005-11-30
US8653104B2 (en) 2014-02-18
ATE345800T1 (de) 2006-12-15
EP1599205B1 (en) 2006-11-22
HK1148225A1 (zh) 2011-09-02
US20130065921A1 (en) 2013-03-14
US20100113515A1 (en) 2010-05-06
AU2004216340B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
US8329731B2 (en) PTEN inhibitor or Maxi-K channels opener
CN105263948B (zh) 用Nutlin-3a和肽抑制肺纤维化
JP2022508183A (ja) 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤
ES2460617T3 (es) Combinación de pilocarpina y tiamazol para tratar la enfermedad de Charcot-Marie-Tooth y los trastornos relacionados
RS67438B1 (sr) Lečenje amiotrofne lateralne skleroze pridopidinom
AU2008229483A1 (en) Kinase protein binding inhibitors
EP2862572B1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
JP2009525025A (ja) ニューロンニコチン受容体リガンドおよびその使用
JP5705136B2 (ja) リードスルー誘導剤、及びナンセンス変異型遺伝性疾患治療薬
JP6796581B2 (ja) ミッシングタンパク質の小分子模倣体を用いた生理機能の回復
US20240082312A1 (en) Compositions and methods for williams syndrome (ws) therapy
KR20200043401A (ko) 신경 질환을 치료하기 위한 방법 및 조성물
HK1091409B (en) Pten inhibitor or maxi-k channels opener
HK1148225B (en) Pten inhibitor or maxi-k channel opener
WO2007037258A1 (ja) 注意欠陥・多動性障害の治療薬

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired